Dr. Lal PathLabs Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Dr. Lal PathLabs de 15.4% y 10.7% por año respectivamente. Se prevé que el BPA crezca en un 15.3% al año. Se espera que la rentabilidad financiera sea de 20.2% en 3 años.

Información clave

15.4%

Tasa de crecimiento de los beneficios

15.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	26.9%
Tasa de crecimiento de los ingresos	10.7%
Rentabilidad financiera futura	20.2%
Cobertura de analistas	Good
Última actualización	23 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04

Recent updates

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Sep 01

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Jul 31

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 23

Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

Jun 11

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

May 25

Do Dr. Lal PathLabs's (NSE:LALPATHLAB) Earnings Warrant Your Attention?

Apr 28

Is Dr. Lal PathLabs (NSE:LALPATHLAB) A Risky Investment?

Feb 17

With EPS Growth And More, Dr. Lal PathLabs (NSE:LALPATHLAB) Is Interesting

Jan 20

Why You Should Care About Dr. Lal PathLabs' (NSE:LALPATHLAB) Strong Returns On Capital

Dec 06

Here's Why I Think Dr. Lal PathLabs (NSE:LALPATHLAB) Might Deserve Your Attention Today

Oct 13

Previsiones de crecimiento de beneficios e ingresos

NSEI:LALPATHLAB - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	31,880	5,451	6,624	N/A	2
3/31/2026	27,823	4,827	5,719	N/A	19
3/31/2025	24,939	4,159	5,075	N/A	19
3/31/2024	22,359	3,569	4,238	N/A	20
12/31/2023	21,722	3,298	N/A	N/A	N/A
9/30/2023	21,227	3,013	4,767	5,198	N/A
6/30/2023	20,552	2,638	N/A	N/A	N/A
3/31/2023	20,169	2,388	4,115	4,560	N/A
12/31/2022	20,114	2,435	N/A	N/A	N/A
9/30/2022	20,189	2,480	-824	3,884	N/A
6/30/2022	19,835	2,713	N/A	N/A	N/A
3/31/2022	20,874	3,448	-294	4,467	N/A
12/31/2021	20,329	3,669	N/A	N/A	N/A
9/30/2021	19,884	4,041	4,609	5,327	N/A
6/30/2021	19,219	3,944	N/A	N/A	N/A
3/31/2021	15,813	2,916	3,386	3,982	N/A
12/31/2020	14,520	2,407	N/A	N/A	N/A
9/30/2020	13,275	2,003	2,259	2,821	N/A
6/30/2020	12,612	1,955	N/A	N/A	N/A
3/31/2020	13,304	2,259	2,043	2,839	N/A
12/31/2019	13,298	2,405	N/A	N/A	N/A
9/30/2019	12,944	2,322	2,199	2,619	N/A
6/30/2019	12,463	2,086	N/A	N/A	N/A
3/31/2019	12,034	1,992	1,765	2,185	N/A
12/31/2018	11,691	1,923	N/A	N/A	N/A
9/30/2018	11,393	1,825	N/A	N/A	N/A
6/30/2018	10,999	1,761	N/A	N/A	N/A
3/31/2018	10,569	1,707	1,246	1,971	N/A
12/31/2017	10,100	1,617	N/A	N/A	N/A
9/30/2017	9,548	1,565	N/A	N/A	N/A
6/30/2017	9,389	1,586	N/A	N/A	N/A
3/31/2017	9,124	1,546	N/A	1,713	N/A
12/31/2016	8,902	1,576	N/A	N/A	N/A
9/30/2016	8,713	1,876	N/A	N/A	N/A
6/30/2016	8,249	1,413	N/A	N/A	N/A
3/31/2016	7,913	1,322	N/A	1,585	N/A
12/31/2015	7,654	1,201	N/A	N/A	N/A
3/31/2015	6,596	908	N/A	1,218	N/A
3/31/2014	5,579	763	N/A	980	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (15.4% al año) de LALPATHLAB es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Se prevé que los beneficios (15.4% al año) de LALPATHLAB crezcan menos que el mercado Indian (18% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de LALPATHLAB crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (10.7% al año) de LALPATHLAB crezcan más rápidamente que los del mercado Indian (10.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 10.7% al año) de LALPATHLAB crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de LALPATHLAB sea alta dentro de 3 años (20.2%)

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Dr. Lal PathLabs Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Price target increased by 8.0% to ₹2,353

Price target increased by 7.2% to ₹2,091

Price target decreased to ₹2,536

Price target decreased to ₹2,829

Price target increased to ₹3,286

Recent updates

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

MD & Director recently sold ₹33m worth of stock

MD & Director recently sold ₹23m worth of stock

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

MD & Director recently sold ₹43m worth of stock

Upcoming dividend of ₹12.00 per share at 0.7% yield

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24

Dr. Lal PathLabs Limited to Report Q3, 2024 Results on Feb 01, 2024

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Chief Executive Officer recently sold ₹7.6m worth of stock

Chief Executive Officer recently sold ₹2.6m worth of stock

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Non Executive Director recently sold ₹7.8m worth of stock

Price target increased by 8.0% to ₹2,353

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2024 Results on Nov 02, 2023

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023

Dr. Lal PathLabs Limited Announces Change in Directorate

Dr. Lal PathLabs Limited Announces Change in Directorate

MD & Director recently sold ₹32m worth of stock

Upcoming dividend of ₹12.00 per share at 0.5% yield

Price target increased by 7.2% to ₹2,091

Dr. Lal PathLabs Limited, Annual General Meeting, Sep 12, 2023

Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings released: EPS: ₹9.95 (vs ₹6.97 in 1Q 2023)

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

MD & Director recently sold ₹41m worth of stock

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves Appointment of Vinay Gujral as Company Secretary

Full year 2023 earnings: EPS and revenues miss analyst expectations

MD & Director recently sold ₹14m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹41m worth of stock

Rajat Kalra Resigns as Company Secretary and Compliance Officer of Dr. Lal Pathlabs Limited, Effective on or Before May 04, 2023

Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited (NSEI:LALPATHLAB) agreed to acquire additional 10% stake in Aprl Pathlabs Private Limited for INR 7.5 million.

Dr. Lal PathLabs Limited to Report Q3, 2023 Results on Feb 02, 2023

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Chief Executive Officer recently sold ₹3.6m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹61m worth of stock

MD & Director recently sold ₹57m worth of stock

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2023 Results on Nov 08, 2022

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends

MD & Director recently sold ₹33m worth of stock

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Non Executive Director recently sold ₹2.5m worth of stock

MD & Director recently sold ₹117m worth of stock

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Dr. Lal Pathlabs Limited Declares an Interim Dividend for the Financial Year 2022-23, Payable on or Before August 26, 2022

First quarter 2023 earnings: EPS misses analyst expectations

Dr. Lal PathLabs Limited to Report Q1, 2023 Results on Jul 28, 2022

Dr. Lal Pathlabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Non-Executive Director recently sold ₹164m worth of stock

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Price target decreased to ₹2,536

Upcoming dividend of ₹6.00 per share

Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

Dr. Lal Pathlabs Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Investor sentiment improved over the past week